At a House hearing on April 16, 2026, HHS Secretary Robert F. Kennedy Jr. defended the FDA and Commissioner Marty Makary after a tough round of questioning from Republican lawmakers. The exchange came during Kennedy’s long testimony session on Capitol Hill, described by STAT as a “testimony marathon.” He acknowledged the pressure Makary faces but stood by his leadership of the agency. That moment mattered, it was one of those rare times when an administration figure drew a clear line of support instead of retreating into careful talking points.
The defense landed in the middle of turbulent politics around FDA oversight. Kennedy’s backing of Makary shows that the administration intends to hold its ground behind its FDA chief despite growing partisan attacks over regulatory tempo and transparency. The White House appears determined to maintain regulatory continuity through 2026, a critical stance as several headline-making drug and device reviews approach decision dates later in the year. Continuity isn’t glamorous, but in this space, it’s currency.
If congressional scrutiny heats up further, the FDA’s review schedule will likely feel the drag. That’s the risk point for drug sponsors and investors betting on predictable timelines. For payers and PBMs, a clogged approval pipeline can throw off launch sequencing and formulary planning well into 2027. Keep an eye on how Makary and Kennedy navigate the next committee sessions. If Kennedy continues taking the political heat in Makary’s place, agency independence might hold for now, but the partisan divide could widen just as the next appropriations debate kicks off. And that’s where things usually get messy.
